DECREASE

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer detected by PSMA.

Enquire

Trial overview

Topic

Prostate cancer

Eligibility criteria

To be considered for the study you must meet the following criteria:

aged 18+
Confirmed prostate adenocarcinoma with castration-resistance
Baseline PSA of at least 2ng/ml, PSA doubling time of 10 months or less and at least 2 consecutive rises

Study details

Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate resistant prostate cancer when using conventional imaging. However, it is estimated that >90% of patients have disease apparent whenusing PSMA PET. This study investigates the use of local consolidation radiotherapy in this cohort of men.

Further information

For more information regarding this trial click here.

Location

North Shore

Hurstville (Oncology)

Fiona Stanley Hospital (Oncology)

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

First name *

Last name *

Email *

Phone *

State *

Postcode *

What is the reason for enquiry?

How would you prefer to be contacted? *

Phone

By submitting you acknowledge we will use the information you are providing to contact you about your enquiry. For more information about how we handle your personal information, please refer to the GenesisCare Privacy Policy.

DECREASE

Trial overview

Thank you for submitting.

An unexpected error has occurred.

How can we help?

GenesisCare

Website policies

Contact us

Media & Social